Men have a higher prevalence of PMF and a lower prevalence of ET at presentation, worse survival, and shorter time to MF transformation. (A) Men were more likely to present with PMF compared with women (P < .001), and women were more likely to present with ET (P < .001) in the entire cohort; male subjects with a JAK2 mutation have a higher prevalence of PMF (P < .001) and a lower prevalence of ET (P = .001) at presentation. Similarly, JAK2-negative men have a higher prevalence of PMF (P = .04) at presentation. The prevalence of PMF was similar among women and men only in the CALR mutation subgroup. The frequency of PMF in men in the MPL and triple-negative subgroups was higher compared with women (50% vs 13.3% [P = .290] and 50% vs 25.7% [P = .243], respectively), but the differences did not reach significance. (B) Kaplan-Meier curves showing that the survival of men from the whole cohort was significantly worse compared with women (P < .001). (C) Kaplan-Meier analysis showing that men had shorter sMF-free survival (P = .002).